Publications

Found 1 results
Filters: Author is S. Kocaturk-Sel  [Clear All Filters]
2011
M. B. Yilmaz, Pazarbasi, A., Guzel, A. I., Kocaturk-Sel, S., Kasap, H., Kasap, M., Urunsak, I. F., Basaran, S., Alptekin, D., and Demirhan, O., Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey, vol. 10, pp. 1999-2008, 2011.
Berstein LM, Imyanitov EN, Gamajunova VB, Kovalevskij AJ, et al. (2002). CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Lett. 180: 47-53. http://dx.doi.org/10.1016/S0304-3835(02)00019-8 Bulun SE, Lin Z, Imir G, Amin S, et al. (2005). Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol. Rev. 57: 359-383. http://dx.doi.org/10.1124/pr.57.3.6 PMid:16109840 Carbonell SS, Masi L, Marini F, Del Monte F, et al. (2005). Genetics and pharmacogenetics of osteoporosis. J. Endocrinol. Invest. 28: 2-7. Compston J (2010). Osteoporosis: social and economic impact. Radiol. Clin. North Am. 48: 477-482. http://dx.doi.org/10.1016/j.rcl.2010.02.010 PMid:20609886 Eriksson AL, Lorentzon M, Vandenput L, Labrie F, et al. (2009). Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J. Clin. Endocrinol. Metab. 94: 1033-1041. http://dx.doi.org/10.1210/jc.2008-1283 Feigelson HS, McKean-Cowdin R and Henderson BE (2002). Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17: 445-446. http://dx.doi.org/10.1093/mutage/17.5.445 PMid:12202634 Gennari L, Becherini L, Falchetti A, Masi L, et al. (2002). Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. J. Steroid Biochem. Mol. Biol. 81: 1-24. http://dx.doi.org/10.1016/S0960-0760(02)00043-2 Kado N, Kitawaki J, Obayashi H, Ishihara H, et al. (2002). Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum. Reprod. 17: 897-902. http://dx.doi.org/10.1093/humrep/17.4.897 PMid:11925378 Khosla S (2010). Update on estrogens and the skeleton. J. Clin. Endocrinol. Metab. 95: 3569-3577. http://dx.doi.org/10.1210/jc.2010-0856 Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, et al. (2000). A TA repeat polymorphism in the estrogen receptor gene is associated with osteoporotic fractures but polymorphisms in the first exon and intron are not. J. Bone Miner. Res. 15: 2222-2230. http://dx.doi.org/10.1359/jbmr.2000.15.11.2222 PMid:11092403 Lorentzon M, Swanson C, Eriksson AL, Mellstrom D, et al. (2006). Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study. J. Bone Miner. Res. 21: 332-339. http://dx.doi.org/10.1359/JBMR.051026 PMid:16418790 Masi L, Becherini L, Gennari L, Amedei A, et al. (2001). Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J. Clin. Endocrinol. Metab. 86: 2263-2269. http://dx.doi.org/10.1210/jc.86.5.2263 Nelson LR and Bulun SE (2001). Estrogen production and action. J. Am. Acad. Dermatol. 45: S116-S124. http://dx.doi.org/10.1067/mjd.2001.117432 PMid:11511861 Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, et al. (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann. Oncol. 20: 1489-1498. http://dx.doi.org/10.1093/annonc/mdp033 PMid:19474112    PMCid:2731016 Ralston SH (2003). Genetic determinants of susceptibility to osteoporosis. Curr. Opin. Pharmacol. 3: 286-290. http://dx.doi.org/10.1016/S1471-4892(03)00033-X Riancho JA, Zarrabeitia MT, Valero C, Sanudo C, et al. (2005). Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density. Bone 36: 917-925. http://dx.doi.org/10.1016/j.bone.2005.01.004 PMid:15794932 Riggs BL, Khosla S and Melton LJ (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23: 279-302. http://dx.doi.org/10.1210/er.23.3.279 PMid:12050121 Sharp L, Cardy AH, Cotton SC and Little J (2004). CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. a HuGE review. Am. J. Epidemiol. 160: 729-740. http://dx.doi.org/10.1093/aje/kwh287 PMid:15466495 Siegelmann-Danieli N and Buetow KH (1999). Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br. J. Cancer 79: 456-463. http://dx.doi.org/10.1038/sj.bjc.6690071 PMid:10027313    PMCid:2362434 Simpson ER (2000). Role of aromatase in sex steroid action. J. Mol. Endocrinol. 25: 149-156. http://dx.doi.org/10.1677/jme.0.0250149 PMid:11013343 Sipos W, Pietschmann P, Rauner M, Kerschan-Schindl K, et al. (2009). Pathophysiology of osteoporosis. Wien. Med. Wochenschr. 159: 230-234. http://dx.doi.org/10.1007/s10354-009-0647-y PMid:19484205 Somner J, McLellan S, Cheung J, Mak YT, et al. (2004). Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 89: 344-351. http://dx.doi.org/10.1210/jc.2003-030164 Tofteng CL, Kindmark A, Brandstrom H, Abrahamsen B, et al. (2004). Polymorphisms in the CYP19 and AR genes - relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: the Danish osteoporosis prevention study. Calcif. Tissue Int. 74: 25-34. http://dx.doi.org/10.1007/s00223-002-2158-3 PMid:14517714 Waltman NL, Ott CD, Twiss JJ, Gross GJ, et al. (2008). Bone mineral density and bone turnover in postmenopausal women treated for breast cancer. Cancer Nurs. 31: 182-190. http://dx.doi.org/10.1097/01.NCC.0000305722.75647.26 PMid:18453874 Ye Z and Parry JM (2002). The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17: 119-126. http://dx.doi.org/10.1093/mutage/17.2.119 PMid:11880540 Zmuda JM, Cauley JA, Kuller LH and Ferrell RE (2001). A common promotor variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men. J. Bone Miner. Res. 16: 911-917. http://dx.doi.org/10.1359/jbmr.2001.16.5.911 PMid:11341336